AAAAAA

   
Results: 1-19 |
Results: 19
A PHASE-I STUDY OF LIPOSOME-FORMULATED CISPLATIN (SPI-77(R)) GIVEN EVERY 3 WEEKS IN PATIENTS WITH ADVANCED CANCER
Authors: DEMARIO MD VOGELZANG NJ JANISCH L HUMPHRISS E MANI S TONDA M AMANTEA MA RATAIN MJ PENDYALA L
Citation: Md. Demario et al., A PHASE-I STUDY OF LIPOSOME-FORMULATED CISPLATIN (SPI-77(R)) GIVEN EVERY 3 WEEKS IN PATIENTS WITH ADVANCED CANCER, Annals of oncology, 9, 1998, pp. 466-466
POPULATION PHARMACOKINETIC DETERMINATION OF THE EFFECT OF FOOD ON THEPHARMACOKINETICS OF ORAL 5-FLUOROURACIL (FU) AND ENILURACIL (776C85, 776)
Authors: SHEPARD DR MANI S JANISCH L FLEMING GF SCHILSKY RL RATAIN MJ
Citation: Dr. Shepard et al., POPULATION PHARMACOKINETIC DETERMINATION OF THE EFFECT OF FOOD ON THEPHARMACOKINETICS OF ORAL 5-FLUOROURACIL (FU) AND ENILURACIL (776C85, 776), Annals of oncology, 9, 1998, pp. 600-600
PHASE-I CLINICAL AND PHARMACOLOGICAL STUDY OF ENILURACIL PLUS FLUOROURACIL IN PATIENTS WITH ADVANCED CANCER
Authors: SCHILSKY RL HOHNEKER J RATAIN MJ JANISCH L SMETZER L LUCAS VS KHOR SP DIASIO R VONHOFF DD BURRIS HA
Citation: Rl. Schilsky et al., PHASE-I CLINICAL AND PHARMACOLOGICAL STUDY OF ENILURACIL PLUS FLUOROURACIL IN PATIENTS WITH ADVANCED CANCER, Journal of clinical oncology, 16(4), 1998, pp. 1450-1457
PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF ORAL 9-AMINOCAMPTOTHECIN (NSC-603071)
Authors: MANI S IYER L JANISCH L WANG XL FLEMING GF SCHILSKY RL RATAIN MJ
Citation: S. Mani et al., PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF ORAL 9-AMINOCAMPTOTHECIN (NSC-603071), Cancer chemotherapy and pharmacology, 42(1), 1998, pp. 84-87
EVALUATION OF NEUROPATHY IN PATIENTS ON SURAMIN TREATMENT
Authors: SOLIVEN B DHAND UK KOBAYASHI K ARORA R MARTIN B PETERSEN MV JANISCH L VOGELZANG NJ VOKES EE RATAIN MJ
Citation: B. Soliven et al., EVALUATION OF NEUROPATHY IN PATIENTS ON SURAMIN TREATMENT, Muscle & nerve, 20(1), 1997, pp. 83-91
INDIVIDUALIZED DOSING OF AMONAFIDE BASED ON A PHARMACODYNAMIC MODEL INCORPORATING ACETYLATOR PHENOTYPE AND GENDER
Authors: RATAIN MJ MICK R JANISCH L BEREZIN F SCHILSKY RL VOGELZANG NJ KUT M
Citation: Mj. Ratain et al., INDIVIDUALIZED DOSING OF AMONAFIDE BASED ON A PHARMACODYNAMIC MODEL INCORPORATING ACETYLATOR PHENOTYPE AND GENDER, Pharmacogenetics, 6(1), 1996, pp. 93-101
PHASE-I STUDY OF SURAMIN ADMINISTERED BY INTERMITTENT INFUSION WITHOUT ADAPTIVE-CONTROL TO CANCER-PATIENTS - UPDATE OF 2 EXPANDED DOSE LEVELS NEAR THE MAXIMALLY TOLERATED DOSE
Authors: KOBAYASHI K VOKES EE VOGELZANG NJ JANISCH L SOLIVEN B RATAIN MJ
Citation: K. Kobayashi et al., PHASE-I STUDY OF SURAMIN ADMINISTERED BY INTERMITTENT INFUSION WITHOUT ADAPTIVE-CONTROL TO CANCER-PATIENTS - UPDATE OF 2 EXPANDED DOSE LEVELS NEAR THE MAXIMALLY TOLERATED DOSE, Journal of clinical oncology, 14(9), 1996, pp. 2622-2623
MINERALOCORTICOID INSUFFICIENCY DUE TO SURAMIN THERAPY
Authors: KOBAYASHI K WEISS RE VOGELZANG NJ VOKES EE JANISCH L RATAIN MJ
Citation: K. Kobayashi et al., MINERALOCORTICOID INSUFFICIENCY DUE TO SURAMIN THERAPY, Cancer, 78(11), 1996, pp. 2411-2420
PHASE-I STUDY OF ESCALATING DOSES OF MITOXANTRONE AND PACLITAXEL WITHGRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR SUPPORT
Authors: FLEMING GF JANISCH L VOGELZANG NJ VOKES EE RATAIN MJ
Citation: Gf. Fleming et al., PHASE-I STUDY OF ESCALATING DOSES OF MITOXANTRONE AND PACLITAXEL WITHGRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR SUPPORT, Cancer, 77(11), 1996, pp. 2308-2312
KERATOACANTHOMAS AND SKIN NEOPLASMS ASSOCIATED WITH SURAMIN THERAPY
Authors: KOBAYASHI K PEZEN DS VOGELZANG NJ MEDENICA M JANISCH L RATAIN MJ VOKES EE SOLTANI K
Citation: K. Kobayashi et al., KERATOACANTHOMAS AND SKIN NEOPLASMS ASSOCIATED WITH SURAMIN THERAPY, Archives of dermatology, 132(1), 1996, pp. 96-98
PHASE-I STUDY OF SURAMIN GIVEN BY INTERMITTENT INFUSION WITHOUT ADAPTIVE-CONTROL IN PATIENTS WITH ADVANCED CANCER
Authors: KOBAYASHI K VOKES EE VOGELZANG NJ JANISCH L SOLIVEN B RATAIN MJ
Citation: K. Kobayashi et al., PHASE-I STUDY OF SURAMIN GIVEN BY INTERMITTENT INFUSION WITHOUT ADAPTIVE-CONTROL IN PATIENTS WITH ADVANCED CANCER, Journal of clinical oncology, 13(9), 1995, pp. 2196-2207
ENCEPHALOPATHY IS THE DOSE-LIMITING TOXICITY OF INTRAVENOUS HEPSULFAM- RESULTS OF A PHASE-I TRIAL IN PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES
Authors: LARSON RA GELLER RB JANISCH L MILTON J GROCHOW LB RATAIN MJ
Citation: Ra. Larson et al., ENCEPHALOPATHY IS THE DOSE-LIMITING TOXICITY OF INTRAVENOUS HEPSULFAM- RESULTS OF A PHASE-I TRIAL IN PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES, Cancer chemotherapy and pharmacology, 36(3), 1995, pp. 204-210
PHASE-I TRIAL OF THIOTEPA, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AND PREDNISONE OR PENTOXIFYLLINE IN PATIENTS WITH REFRACTORY SOLID TUMORS
Authors: DEVINE SM RATAIN MJ JANISCH L RICHARDS JM WILLIAMS SF SCHILSKY RL VOGELZANG NJ SKOSEY C
Citation: Sm. Devine et al., PHASE-I TRIAL OF THIOTEPA, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AND PREDNISONE OR PENTOXIFYLLINE IN PATIENTS WITH REFRACTORY SOLID TUMORS, Oncology Reports, 1(1), 1994, pp. 213-216
SEQUENTIAL THERAPY WITH DACARBAZINE AND CARMUSTINE - A PHASE-I STUDY
Authors: MITCHELL RB DOLAN ME JANISCH L VOGELZANG NJ RATAIN MJ SCHILSKY RL
Citation: Rb. Mitchell et al., SEQUENTIAL THERAPY WITH DACARBAZINE AND CARMUSTINE - A PHASE-I STUDY, Cancer chemotherapy and pharmacology, 34(6), 1994, pp. 509-514
EVALUATION OF NEUROPATHY IN PATIENTS ON SURAMIN TREATMENT
Authors: ARORA R DHAND UK KOBAYASHI K VOKES EE MARTIN B JANISCH L RATAIN MJ SOLIVEN B
Citation: R. Arora et al., EVALUATION OF NEUROPATHY IN PATIENTS ON SURAMIN TREATMENT, Neurology, 44(4), 1994, pp. 10000306-10000306
A PHASE-I STUDY OF SURAMIN (SUR) IN PATIENTS WITH ADVANCED CANCER (CA)
Authors: KOBAYASHI K VOKES EE JANISCH L PARKS C VOGELZANG NJ RATAIN MJ
Citation: K. Kobayashi et al., A PHASE-I STUDY OF SURAMIN (SUR) IN PATIENTS WITH ADVANCED CANCER (CA), Clinical pharmacology and therapeutics, 55(2), 1994, pp. 190-190
PHASE-I AND PHARMACOKINETIC STUDY OF A NEW ANTINEOPLASTIC AGENT - PYRAZINE DIAZOHYDROXIDE (NSC-361456)
Authors: VOGELZANG NJ MICK R JANISCH L BEREZIN F SCHILSKY RL RATAIN MJ
Citation: Nj. Vogelzang et al., PHASE-I AND PHARMACOKINETIC STUDY OF A NEW ANTINEOPLASTIC AGENT - PYRAZINE DIAZOHYDROXIDE (NSC-361456), Cancer research, 54(1), 1994, pp. 114-119
PROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS TREATED IN PHASE-I CLINICAL-TRIALS
Authors: JANISCH L MICK R SCHILSKY RL VOGELZANG NJ OBRIEN S KUT M RATAIN MJ
Citation: L. Janisch et al., PROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS TREATED IN PHASE-I CLINICAL-TRIALS, Cancer, 74(7), 1994, pp. 1965-1973
PHASE-I STUDY OF AMONAFIDE DOSING BASED ON ACETYLATOR PHENOTYPE
Authors: RATAIN MJ MICK R BEREZIN F JANISCH L SCHILSKY RL VOGELZANG NJ LANE LB
Citation: Mj. Ratain et al., PHASE-I STUDY OF AMONAFIDE DOSING BASED ON ACETYLATOR PHENOTYPE, Cancer research, 53(10), 1993, pp. 2304-2308
Risultati: 1-19 |